Evidence map›Paper›PMID 29618808›Full record

ReviewNature reviews. Neuroscience2018

Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics.

Mark A Petersen, Jae Kyu Ryu, Katerina Akassoglou

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 305 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
305citing papers in PubMed, 1 pooled it
27.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

305 citing papers in PubMed, 1 synthesis or guideline pooled it, 527 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  7. Article
  8. Article
  9. Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

245 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mark A PetersenGladstone Institutes, San Francisco, CA USA.
Jae Kyu RyuGladstone Institutes, San Francisco, CA USA.
Katerina AkassoglouGladstone Institutes, San Francisco, CA USA.
Gladstone Institutes · USUniversity of California, San Francisco · US

Funding

Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Neurovascular Interactions: Mechanisms, imaging, therapeutic potentialR35NS097976 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI AKASSOGLOU, KATERINA · 2016 to 2023
$11.1M
Child Health Career Development Program at UCSFK12HD072222 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIERO, DONNA M. · 2013 to 2017
$2.0M
American Heart Association-American Stroke Association 16SDG30170014NICHD NIH HHS K12 HD000850NICHD NIH HHS K12 HD072222NINDS NIH HHS R35 NS097976
6 · The paper itself

Abstract

The blood coagulation protein fibrinogen is deposited in the brain in a wide range of neurological diseases and traumatic injuries with blood-brain barrier (BBB) disruption. Recent research has uncovered pleiotropic roles for fibrinogen in the activation of CNS inflammation, induction of scar formation in the brain, promotion of cognitive decline and inhibition of repair. Such diverse roles are possible in part because of the unique structure of fibrinogen, which contains multiple binding sites for cellular receptors and proteins expressed in the nervous system. The cellular and molecular mechanisms underlying the actions of fibrinogen are beginning to be elucidated, providing insight into its involvement in neurological diseases, such as multiple sclerosis, Alzheimer disease and traumatic CNS injury. Selective drug targeting to suppress the damaging functions of fibrinogen in the nervous system without affecting its beneficial effects in haemostasis opens a new fibrinogen therapeutics pipeline for neurological disease.

Indexed as

Nervous System DiseasesNeuroimagingAnimalsFibrinogenHumansFibrinogen

Identifiers

PMID29618808
PMCPMC6743980
OpenAlexW2796437903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.